Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

sMICA and its emerging role as a prognostic and diagnostic indicator in systemic malignancies besides hepatocellular carcinoma.

Kapoor S.

Chin J Cancer. 2013 Apr;32(4):224. doi: 10.5732/cjc.012.10234. Epub 2013 Mar 15. No abstract available.

2.

Prognostic value of soluble MICA levels in the serum of patients with advanced hepatocellular carcinoma.

Li JJ, Pan K, Gu MF, Chen MS, Zhao JJ, Wang H, Liang XT, Sun JC, Xia JC.

Chin J Cancer. 2013 Mar;32(3):141-8. doi: 10.5732/cjc.012.10025. Epub 2012 Jun 14.

3.

Impairment of natural killer cell and dendritic cell functions by the soluble form of MHC class I-related chain A in advanced human hepatocellular carcinomas.

Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, Hayashi N.

J Hepatol. 2005 Dec;43(6):1013-20. Epub 2005 Jun 29.

PMID:
16168521
4.

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.

Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M, Kaiser S, Jobst J, Smirnow I, Wagner A, Steinle A, Salih HR.

Cancer Res. 2005 Jul 15;65(14):6321-9.

5.

Targeting blockage of STAT3 in hepatocellular carcinoma cells augments NK cell functions via reverse hepatocellular carcinoma-induced immune suppression.

Sun X, Sui Q, Zhang C, Tian Z, Zhang J.

Mol Cancer Ther. 2013 Dec;12(12):2885-96. doi: 10.1158/1535-7163.MCT-12-1087. Epub 2013 Oct 9.

6.

Identification and functional analysis of ligands for natural killer cell activating receptors in colon carcinoma.

Zhang Z, Su T, He L, Wang H, Ji G, Liu X, Zhang Y, Dong G.

Tohoku J Exp Med. 2012;226(1):59-68. doi: 10.6120/tjem.226.59.

7.

Fibroblast growth factor-2 enhances NK sensitivity of hepatocellular carcinoma cells.

Tsunematsu H, Tatsumi T, Kohga K, Yamamoto M, Aketa H, Miyagi T, Hosui A, Hiramatsu N, Kanto T, Hayashi N, Takehara T.

Int J Cancer. 2012 Jan 15;130(2):356-64. doi: 10.1002/ijc.26003. Epub 2011 Apr 25.

8.

NKG2D and its ligands: key to immunotherapy of liver cancer?

Mondelli MU.

J Hepatol. 2012 Feb;56(2):308-10. doi: 10.1016/j.jhep.2011.07.008. Epub 2011 Jul 26. No abstract available.

9.

The soluble major histocompatibility complex class I-related chain A protein reduced NKG2D expression on natural killer and T cells from patients with prolactinoma and non-secreting pituitary adenoma.

Ma L, Li G, Su Y, He Q, Zhang C, Zhang J.

J Clin Neurosci. 2010 Feb;17(2):241-7. doi: 10.1016/j.jocn.2009.05.023. Epub 2009 Dec 31.

PMID:
20045334
10.

Augmented serum level of major histocompatibility complex class I-related chain A (MICA) protein and reduced NKG2D expression on NK and T cells in patients with cervical cancer and precursor lesions.

Arreygue-Garcia NA, Daneri-Navarro A, del Toro-Arreola A, Cid-Arregui A, Gonzalez-Ramella O, Jave-Suarez LF, Aguilar-Lemarroy A, Troyo-Sanroman R, Bravo-Cuellar A, Delgado-Rizo V, Garcia-Iglesias T, Hernandez-Flores G, Del Toro-Arreola S.

BMC Cancer. 2008 Jan 21;8:16. doi: 10.1186/1471-2407-8-16.

11.

Natural killer cell activity in patients with hepatocellular carcinoma: a new prognostic indicator after hepatectomy.

Taketomi A, Shimada M, Shirabe K, Kajiyama K, Gion T, Sugimachi K.

Cancer. 1998 Jul 1;83(1):58-63.

PMID:
9655293
12.

Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence.

Kamimura H, Yamagiwa S, Tsuchiya A, Takamura M, Matsuda Y, Ohkoshi S, Inoue M, Wakai T, Shirai Y, Nomoto M, Aoyagi Y.

J Hepatol. 2012 Feb;56(2):381-8. doi: 10.1016/j.jhep.2011.06.017. Epub 2011 Jul 12.

PMID:
21756848
13.

[Expression and clinical significance of CD8+natural killer T cell stimulatory receptor NKG2D in peripheral blood of lung cancer patients].

Cheng N, Han F, Wang Y, Mai X, Su W.

Zhongguo Fei Ai Za Zhi. 2010 Oct;13(10):962-7. doi: 10.3779/j.issn.1009-3419.2010.10.06. Chinese.

14.

Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.

Duan X, Deng L, Chen X, Lu Y, Zhang Q, Zhang K, Hu Y, Zeng J, Sun W.

Med Oncol. 2011 Jun;28(2):466-74. doi: 10.1007/s12032-010-9480-9. Epub 2010 Mar 31.

PMID:
20354827
15.

[Characteristics of peripheral NK cells in hepatocellular carcinoma patients].

Zhou L, Cai L, Zhang Z, Yang YP, Wang FS.

Zhonghua Gan Zang Bing Za Zhi. 2010 Feb;18(2):136-9. doi: 10.3760/cma.j.issn.1007-3418.2010.02.013. Chinese.

PMID:
20196954
16.

[Expression and significance of the NK cell receptors in primary hepatocellular carcinoma and paracancerous tissues].

Jiang JH, Zhou ZF, Li JY, Ye YB, Chen Q.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2012 May;28(5):529-32. Chinese.

PMID:
22558993
17.
18.

Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer.

Huang B, Sikorski R, Sampath P, Thorne SH.

J Immunother. 2011 Apr;34(3):289-96. doi: 10.1097/CJI.0b013e31820e1b0d.

19.

[Natural killer cell activity of the peripheral blood in patients with hepatocellular carcinoma].

Lin ZY, Weng HZ, Tang ZY, Wang QD.

Zhonghua Zhong Liu Za Zhi. 1986 Nov;8(6):417-20. Chinese.

PMID:
2438105
20.
Items per page

Supplemental Content

Write to the Help Desk